Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection

C Li1, L S Fung, S Chung

  • 1Department of Medicine, University of Toronto, Canada.

Insights

A neutralizing antibody targeting monocyte/macrophage procoagulant activity (PCA) protected mice from severe liver disease and death caused by murine hepatitis virus strain 3 (MHV-3) infection. This suggests PCA is a key mediator in MHV-3 pathogenesis.

Area of Science:

  • Virology
  • Immunology
  • Hepatology

Background:

  • Monocyte/macrophage procoagulant activity (PCA) is implicated in murine hepatitis virus strain 3 (MHV-3) pathogenesis.
  • PCA induction by MHV-3 correlates with host resistance/susceptibility.
  • BALB/cJ mice infected with MHV-3 exhibit severe liver disease and mortality.

Purpose of the Study:

  • To investigate the role of PCA in MHV-3-induced liver injury.
  • To evaluate the therapeutic potential of a PCA-neutralizing antibody against MHV-3 infection.

Main Methods:

  • Infection of BALB/cJ mice with MHV-3.
  • Administration of a PCA-neutralizing monoclonal antibody (3D4.3).
  • Assessment of hepatic necrosis, fibrin deposition, PCA expression, and survival rates.

Main Results:

  • MHV-3 infection led to severe hepatitis, necrosis, fibrin deposition, and high mortality.
  • Treatment with the PCA-neutralizing antibody dose-dependently reduced hepatic necrosis and increased survival.
  • Antibody treatment decreased fibrin deposition and PCA expression, with evidence of antibody sequestration.

Conclusions:

  • A neutralizing antibody to PCA effectively protects against fulminant hepatitis and death in MHV-3 infection.
  • PCA is a critical inflammatory mediator in the pathogenesis of MHV-3-induced liver injury.
  • Passive administration of the antibody confers protection, highlighting PCA as a therapeutic target.

Related Concept Videos